ess continuing to perform well 
across the group. This, while Proton Therapys 
performance has been affected by significant 
investments into the future growth of the business 
alongside some delays in backlog conversion. MESSAGE
from Olivier Legrain
CORPORATE BROCHURE 2024
IBA
5